BioLineRx (NASDAQ:BLRX) is up 7% premarket after the European Commission granted Orphan Drug Designation to Motixafortide (BL-8040), for the treatment of pancreatic cancer.
Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.